123 related articles for article (PubMed ID: 33166831)
1. Role of tumor margin and ADC change in defining the need for additional treatments after the first TACE in patients with unresectable HCC.
Shaghaghi M; AliyariG Hasabeh M; Ameli S; Ghadimi M; Hazhirkarzar B; Rezvani Habibabadi R; Tang H; Khoshpouri P; Wu Q; Pandey A; Pandey P; Baghdadi A; Kamel IR
Eur J Radiol; 2020 Dec; 133():109389. PubMed ID: 33166831
[TBL] [Abstract][Full Text] [Related]
2. Post-TACE changes in ADC histogram predict overall and transplant-free survival in patients with well-defined HCC: a retrospective cohort with up to 10 years follow-up.
Shaghaghi M; Aliyari Ghasabeh M; Ameli S; Ghadimi M; Hazhirkarzar B; Rezvani Habibabadi R; Khoshpouri P; Pandey A; Pandey P; Kamel IR
Eur Radiol; 2021 Mar; 31(3):1378-1390. PubMed ID: 32894356
[TBL] [Abstract][Full Text] [Related]
3. Diffusion-weighted imaging of hepatocellular carcinoma before and after transarterial chemoembolization: role in survival prediction and response evaluation.
Labeur TA; Runge JH; Klompenhouwer EG; Klümpen HJ; Takkenberg RB; van Delden OM
Abdom Radiol (NY); 2019 Aug; 44(8):2740-2750. PubMed ID: 31069479
[TBL] [Abstract][Full Text] [Related]
4. Apparent Diffusion Coefficient Can Predict Therapy Response of Hepatocellular Carcinoma to Transcatheter Arterial Chemoembolization.
Drewes R; Heinze C; Pech M; Powerski M; Woidacki K; Wienke A; Surov A; Omari J
Dig Dis; 2022; 40(5):596-606. PubMed ID: 34749359
[TBL] [Abstract][Full Text] [Related]
5. Integrating baseline MR imaging biomarkers into BCLC and CLIP improves overall survival prediction of patients with hepatocellular carcinoma (HCC).
Aliyari Ghasabeh M; Shaghaghi M; Pandey A; Ameli S; Ambale Venkatesh B; Jacob A; Pandey P; Hazhirkarzar B; Luo Y; Rezvani Habibabadi R; Khoshpouri P; Ghadimi M; Kamel IR
Eur Radiol; 2021 Mar; 31(3):1630-1641. PubMed ID: 32910233
[TBL] [Abstract][Full Text] [Related]
6. Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience.
Zhang Y; Huang G; Wang Y; Liang L; Peng B; Fan W; Yang J; Huang Y; Yao W; Li J
Oncologist; 2016 Dec; 21(12):1442-1449. PubMed ID: 27486202
[TBL] [Abstract][Full Text] [Related]
7. Serial diffusion-weighted MRI in patients with hepatocellular carcinoma: Prediction and assessment of response to transarterial chemoembolization. Preliminary experience.
Mannelli L; Kim S; Hajdu CH; Babb JS; Taouli B
Eur J Radiol; 2013 Apr; 82(4):577-82. PubMed ID: 23246330
[TBL] [Abstract][Full Text] [Related]
8. Immediate post-doxorubicin drug-eluting beads chemoembolization Mr Apparent diffusion coefficient quantification predicts response in unresectable hepatocellular carcinoma: A pilot study.
Kokabi N; Camacho JC; Xing M; Edalat F; Mittal PK; Kim HS
J Magn Reson Imaging; 2015 Oct; 42(4):981-9. PubMed ID: 25683022
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of transcatheter arterial chemoembolization with embospheres in treatment of hepatocellular carcinoma.
Hao MZ; Lin HL; Chen QZ; Hu YB; Chen JB; Zheng JX; Zhou D; Zhang H
J Dig Dis; 2017 Jan; 18(1):31-39. PubMed ID: 27987344
[TBL] [Abstract][Full Text] [Related]
10. Transarterial Radioembolization Following Chemoembolization for Unresectable Hepatocellular Carcinoma: Response Based on Apparent Diffusion Coefficient Change is an Independent Predictor for Survival.
Klompenhouwer EG; Dresen RC; Verslype C; Laenen A; Bonne L; Vandecaveye V; Maleux G
Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1716-1726. PubMed ID: 29872894
[TBL] [Abstract][Full Text] [Related]
11. ADC
Wu L; Xu P; Rao S; Yang L; Chen C; Liu H; Fu C; Zeng M
J Magn Reson Imaging; 2017 Sep; 46(3):820-830. PubMed ID: 28276105
[TBL] [Abstract][Full Text] [Related]
12. Early Prediction of the Outcome Using Tumor Markers and mRECIST in Unresectable Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization.
Ichikawa T; Machida N; Sasaki H; Tenmoku A; Kaneko H; Negishi R; Oi I; Fujino MA
Oncology; 2016; 91(6):317-330. PubMed ID: 27784014
[TBL] [Abstract][Full Text] [Related]
13. Association of Addition of Ablative Therapy Following Transarterial Chemoembolization With Survival Rates in Patients With Hepatocellular Carcinoma.
English K; Brodin NP; Shankar V; Zhu S; Ohri N; Golowa YS; Cynamon J; Bellemare S; Kaubisch A; Kinkhabwala M; Kalnicki S; Garg MK; Guha C; Kabarriti R
JAMA Netw Open; 2020 Nov; 3(11):e2023942. PubMed ID: 33151315
[TBL] [Abstract][Full Text] [Related]
14. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
[TBL] [Abstract][Full Text] [Related]
15. Combination Therapy of Radiofrequency Ablation and Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Retrospective Study.
Tang C; Shen J; Feng W; Bao Y; Dong X; Dai Y; Zheng Y; Zhang J
Medicine (Baltimore); 2016 May; 95(20):e3754. PubMed ID: 27196501
[TBL] [Abstract][Full Text] [Related]
16. Role of diffusion-weighted imaging in evaluating therapeutic efficacy after transcatheter arterial chemoembolization for hepatocellular carcinoma.
Kubota K; Yamanishi T; Itoh S; Murata Y; Miyatake K; Yasunami H; Morio K; Hamada N; Nishioka A; Ogawa Y
Oncol Rep; 2010 Sep; 24(3):727-32. PubMed ID: 20664980
[TBL] [Abstract][Full Text] [Related]
17. Nonresectable combined hepatocellular carcinoma and cholangiocarcinoma: analysis of the response and prognostic factors after transcatheter arterial chemoembolization.
Kim JH; Yoon HK; Ko GY; Gwon DI; Jang CS; Song HY; Shin JH; Sung KB
Radiology; 2010 Apr; 255(1):270-7. PubMed ID: 20308463
[TBL] [Abstract][Full Text] [Related]
18. Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis.
Lin CW; Chen YS; Lo GH; Hsu YC; Hsu CC; Wu TC; Yeh JH; Hsiao P; Hsieh PM; Lin HY; Shu CW; Hung CM
BMC Gastroenterol; 2020 Apr; 20(1):99. PubMed ID: 32272898
[TBL] [Abstract][Full Text] [Related]
19. Hepatic resection alone versus in combination with pre- and post-operative transarterial chemoembolization for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis.
Qi X; Liu L; Wang D; Li H; Su C; Guo X
Oncotarget; 2015 Nov; 6(34):36838-59. PubMed ID: 26451613
[TBL] [Abstract][Full Text] [Related]
20. Transarterial chemoembolization combined with Jie-du granule preparation improves the survival outcomes of patients with unresectable hepatocellular carcinoma.
Zhao H; Zhai X; Chen Z; Wan X; Chen L; Shen F; Ling C
Oncotarget; 2017 Jul; 8(28):45234-45241. PubMed ID: 28423370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
